**Market Snapshot: AI Demand and Biotech Triumph**
As broader market futures remained largely unchanged, investors were busy processing a mix of significant headlines—ranging from Morgan Stanley's warning regarding "skyrocketing" demand for AI infrastructure, to the ongoing performance of specific market niches. Discussions surrounding the 2026 Consumer Electronics Show (CES) took center stage, while a selected telecom equity, reportedly flagged by an AI model, registered a staggering gain of 77% across the first two trading days of January. Meanwhile, Bitcoin held steady near the $93,600 mark, even as Strategy disclosed its fourth-quarter losses.
Amidst this varied landscape, biopharmaceutical firm Alumis Inc. (NASDAQ:ALMS) captured significant attention, with its stock skyrocketing by 60% on Tuesday following the release of highly positive late-stage clinical data for its lead psoriasis treatment, envudeucitinib.
**Breakthrough in Psoriasis Treatment**
Alumis, a biopharma company specializing in late-stage development, announced that its novel oral tyrosine kinase 2 (TYK2) inhibitor successfully met all predetermined primary and secondary efficacy endpoints across two pivotal Phase 3 trials designed for moderate-to-severe plaque psoriasis. The statistical significance of the results was exceptionally high, demonstrating superior skin clearing capacity compared to existing therapies.
The data revealed compelling results at the 24-week mark: approximately 65% of patients across both studies achieved a PASI 90 score (indicating a 90% reduction in symptoms), and, notably, over 40% achieved complete skin clearance (PASI 100).
Furthermore, envudeucitinib exhibited rapid therapeutic onset, showing clear differentiation from the placebo cohort as early as Week 4. The drug also proved more effective in achieving skin clearance when directly compared to apremilast in both trials, all while maintaining a consistent and favorable safety profile aligned with earlier observations.
Dr. Jörn Drappa, Alumis’s Chief Medical Officer, underscored the significance of the achievement, stating, “We believe envudeucitinib demonstrates the full promise of TYK2 inhibition. By achieving maximal inhibition of TYK2, the treatment is able to block both IL‑23 and IL‑17 pathways, delivering comprehensive disease management.”
**Regulatory Pathway and Future Trials**
The company is now preparing for regulatory submission and anticipates filing a New Drug Application (NDA) with the FDA during the latter half of 2026.
In addition to plaque psoriasis, Alumis is exploring the potential of envudeucitinib for treating systemic lupus erythematosus (SLE), with results from the Phase 2b trial for that indication scheduled for release in the third quarter of 2026.
Throughout the 24-week study period, the treatment was generally well tolerated. Most adverse events observed were mild to moderate in severity, with commonly reported side effects including nasopharyngitis, headaches, upper respiratory tract infections, and acne.
